Renal Cell Carcinoma Guideline

European Urology

Volumn 51, Issue 6, 2007, Pages 1502-1510

  Ljungberg, Börje ^a   Hanbury, Damian C ^b   Kuczyk, Marcus A ^c   Merseburger, Axel S ^c   Mulders, Peter F A ^d   Patard, Jean Jacques ^e   Sinescu, Ioanel C ^f  

^a UMEÅ UNIVERSITY   (Sweden)

^b LISTER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Diagnosis; Follow up; Guidelines; Recommendations; Renal cell carcinoma; Treatment

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN; INFORMATION; INFORMATION RETRIEVAL; KIDNEY CARCINOMA; MEDLINE; METASTASIS; MONOTHERAPY; NEPHRECTOMY; NEPHRON SPARING SURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PUBLICATION; REGISTER; RETROSPECTIVE STUDY; REVIEW; UROLOGY; VALIDATION STUDY;

EID: 34247390131     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.035     Document Type: Review

References (64)

1. European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.3, 730 entity dictionary (2001). Lyon, France, 2001.
2. Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg 93 (2004) 88-96
3. Kovacs G., Akhtar M., Beckwith B.J., et al. The Heidelberg classification of renal cell tumors. J Pathol 83 (1997) 131-133
4. Pischon T., Lahmann P.H., Boeing H., et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 118 (2006) 728-738
5. Patard J.J., Rodriguez A., Rioux-Leclercq N., Guille F., and Lobel B. Prognostic significance of the mode of detection in renal tumours. BJU Int 90 (2002) 358-363
6. Kato M., Suzuki T., Suzuki Y., Terasawa Y., Sasano H., and Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol 172 (2004) 863-866
7. Novick A.C., and Campbell S.C. Renal tumours. In: Walsh P.C., Retik A.B., Vaughan E.D., and Wein A.J. (Eds). Campbell's urology (2002), WB Saunders, Philadelphia 2672-2731
8. Lee C.T., Katz J., Fearn P.A., and Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol 7 (2002) 135-140
9. Patard J.J., Leray E., Rodriguez A., Rioux-Leclercq N., Guille F., and Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 44 (2003) 226-232
10. Sufrin G., Chasan S., Golio A., and Murphy G.P. Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol 7 (1989) 158-171
11. Heidenreich A., Ravery V., and European Society of Oncological Urology. Preoperative imaging in renal cell cancer. World J Urol 22 (2004) 307-315
12. Hricak H., Demas B.E., Williams R.D., et al. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 154 (1985) 709-715
13. Gupta N.P., Ansari M.S., Khaitan A., et al. Impact of imaging and thrombus level in management of renal cell carcinoma extending to veins. Urol Int 72 (2004) 129-134
14. Sobin LH, Wittekind CH, editors. International Union Against Cancer (UICC). TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002. p. 193-5.
15. Ficarra V., Schips L., Guille F., et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 104 (2005) 968-974
16. Thompson R.H., Leibovich B.C., Cheville J.C., et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol 174 (2005) 1218-1221
17. Han K.R., Bui M.H., Pantuck A.J., et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 169 (2003) 899-903 discussion 903-4
18. Terrone C., Cracco C., Porpiglia F., et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49 (2006) 324-331
19. In: Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I.A. (Eds). Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours (2004), IARC Press, Lyon, France 7
20. Delahunt B., Eble J.N., McCredie M.R., Bethwaite P.B., Stewart J.H., and Bilous A.M. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 32 (2001) 590-595
21. Zhao H., Ljungberg B., Grankvist K., Rasmuson T., Tibshirani R., and Brooks J.D. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 3 (2006) e13
22. Robson C.J., Churchill B.M., and Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 101 (1969) 297-301
23. Kuczyk M., Munch T., Machtens S., et al. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int 89 (2002) 517-522
24. Kuczyk M., Wegener G., and Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 48 (2005) 252-257
25. Glazer A.A., and Novick A.C. Long-term follow-up after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol 155 (1996) 448-450
26. Munro N.P., Woodhams S., Nawrocki J.D., Fletcher M.S., and Thomas P.J. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int 92 (2003) 240-244
27. Hafez K.S., Fergany A.F., and Novick A.C. Nephron-sparing surgery for localized renal carcinoma: impact of tumour size on patient survival, tumour recurrence and TNM staging. J Urol 162 (1999) 1930-1933
28. McKiernan J., Yossepowitch O., Kattan M.W., et al. Partial nephrectomy for renal cortical tumours: pathologic findings and impact on outcome. Urology 60 (2002) 1003-1009
29. Link R.E., Bhayani S.B., Allaf M.E., et al. Exploring the leaning curve, pathological outcomes and perioperative morbidity of laparoscopic partial nephrectomy performed for renal mass. J Urol 173 (2005) 1690-1694
30. Novick A.C. Laparoscopic and partial nephrectomy. Clin Cancer Res 10 (2004) 6322S-6327S
31. Becker F., Siemer S., Humke U., Hack M., Ziegler M., and Stockle M. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: long-term survival data of 216 patients. Eur Urol 49 (2006) 308-313
32. Ono Y., Hattori R., Gotoh M., Yoshino Y., Yoshikawa Y., and Kamihira O. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already?. Curr Opin Urol 15 (2005) 75-78
33. Matin S.F., Gill I.S., Worley S., and Novick A.C. Outcome of laparoscopic radical and open partial nephrectomy for the sporadic 4 cm or less renal tumour with a normal contralateral kidney. J Urol 168 (2002) 1356-1359 discussion 1359-60
34. Lewin J.S., Nour S.G., Connell C.F., et al. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology 232 (2004) 835-845
35. Gill I.S., Remer E.M., Hasan W.A., et al. Renal cryoablation: outcome at 3 years. J Urol 173 (2005) 1903-1907
36. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363 (2004) 594-599
37. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071-1076
38. Ljungberg B., Landberg G., and Alamdari F.I. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 34 (2000) 246-251
39. van der Poel H.G., Roukema J.A., Horenblas S., van Geel A.N., and Debruyne F.M. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35 (1999) 197-203
40. Fossa S.D., Kjolseth I., and Lund G. Radiotherapy of metastases from renal cancer. Eur Urol 8 (1982) 340-342
41. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 (2004) 1665-1672
42. Kavolius J.P., Mastorakos D.P., Pavlovich C., Russo P., Burt M.E., and Brady M.S. Resection of metastatic renal cell carcinoma. J Clin Oncol 16 (1998) 2261-2266
43. Stadler W.M., Huo D., George C., et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170 (2003) 141-1145
44. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353 (1999) 14-17
45. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85 (1993) 622-632
46. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
47. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
48. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
49. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338 (1998) 1272-1278
50. Aass N., De Mulder P.H., Mickisch G.H., et al. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23 (2005) 4172-4178
51. Atzpodien J., Kirchner H., Illiger H.J., et al. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85 (2001) 1130-1136
52. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
53. Patel P.H., Chadalavada R.S., Chaganti R.S., and Motzer R.J. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 612 (2005) 7215-7220
54. Escudier B., Eisen T., Stadler W.M., et al., TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356 (2007) 125-134
55. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
56. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
57. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
58. Hudes G., Carducci M., Tomczak P., et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol (Meeting Abstracts) 24 (2006) LBA4
59. Lam J.S., Shvarts O., Leppert J.T., Figlin R.A., and Belldegrun A.S. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173 (2005) 1853-1862
60. Patard J.J., Shvarts O., Lam J.S., et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171 (2004) 2181-2185
61. Ljungberg B., Alamdari F.I., Rasmuson T., and Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84 (1999) 405-411
62. Kattan M.W., Reuter V., Motzer R.J., Katz J., and Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (2001) 63-67
63. Lam J.S., Shvarts O., Leppert J.T., Pantuck A.J., Figlin R.A., and Belldegrun A.S. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognosticated nomogram and risk group stratification system. J Urol 174 (2005) 466-472
64. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97 (2003) 1663-1671